Vaccination Coverage in Patients with Idiopathic Inflammatory Central Nervous System Demyelinating Diseases at Siriraj Hospital, A Single-center Experience

Onpawee Sangsai; Kamonchanok Aueaphatthanawong

doi:10.33192/smj.v75i8.262732

Authors

Onpawee Sangsai Siriraj Neuroimmunology Center, Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Kamonchanok Aueaphatthanawong Division of Neurology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok

DOI:

https://doi.org/10.33192/smj.v75i8.262732

Keywords:

vaccination, idiopathic inflammatory central nervous system demyelinating diseases, multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody disease

Abstract

Objective: Individuals with Idiopathic Inflammatory Central Nervous System Demyelinating Diseases (CNS-IIDDs) have an elevated risk for infection. Vaccination is key to reducing infection. This study aimed to determine vaccination coverage, the adverse effects of vaccination, and general vaccination knowledge in the patients.

Methods and Methods: A single-center cross-sectional study in the Multiple Sclerosis Clinic at Siriraj Hospital, Thailand, was performed using the designed questionnaires.

Results: Of 100 participants, 90% were female, with a mean (SD) age of 46.2 (12.9). Overall, all received compulsory vaccine coverage. For optional vaccines, the coverage was lower-than-expected, with rates of 3%, 4%, and 3% for human papilloma virus, pneumococcal, and zoster vaccines, respectively. Only 28% of participants received the 2021/2022 seasonal influenza vaccine. The only factor associated with the uptake of the influenza vaccination was the participants’ health coverage. By asking questions to evaluate general vaccination knowledge, two questions related to vaccination and immuno-suppressive agents received the highest percentage of ‘not sure’ responses.

Conclusion: Vaccination coverage was lower than expected among Thai CNS-IIDDs patients, both for optional and seasonal influenza vaccines. Vaccination in these groups of patients should be encouraged to prevent potential infections.

References

Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry. 2018;89(10):1050-6.

Swart EC, Mager D, Parekh N, Heyman RA, Henderson R, Munshi K, et al. Infection incidence and management in multiple sclerosis patients after initiating disease-modifying therapy. Mult Scler Relat Disord. 2021;56:103285.

Zhao Z, Ma C-L, Gu Z-C, Dong Y, Lv Y, Zhong M-K. Incidence and risk of infection associated with fingolimod in patients with multiple sclerosis: a systematic review and meta-analysis of 8,448 patients from 12 randomized controlled trials. Front Immunol. 2021;12:611711.

Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol. 2013;20(8):1153-60.

Thailand TRCoPo. Recommended adult and elderly immunization schedule 2011 [cited 2022 19 September]. Available from: http://www.rcpt.org/index.php/2012-10-03-16-53-39/category/6-2013-02-02-09-02-52.html?download=56%3A2013-02-02-09-08-53.

Farez MF, Correale J, Armstrong MJ, Rae-Grant A, Gloss D, Donley D, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019;93(13):584-94.

Marrie RA, Walld R, Bolton JM, Sareen J, Patten SB, Singer A, et al. Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study. CMAJ Open. 2021;9(2):E510-E21.

Marrie RA, Kosowan L, Cutter GR, Fox R, Salter A. Uptake and attitudes about immunizations in people with multiple sclerosis. Neurol Clin Pract. 2021;11(4):327-34.

Sbragia E, Olobardi D, Novi G, Lapucci C, Cellerino M, Boffa G, et al. Vaccinations in patients with multiple sclerosis: a real-world, single-center experience. Hum Vaccin Immunother. 2022;18(6):2099171.

Achiron A, Dolev M, Menascu S, Zohar D-N, Dreyer-Alster S, Miron S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler. 2021;27(6):864-70.

Cai H, Zhou R, Jiang F, Zeng Q, Yang H. Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy? Mult Scler Relat Disord. 2022;58:103394.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.

Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89.

López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG–associated disorders. JAMA Neurol. 2018;75(11):1355-63.

Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499-505.

Kidd D, Burton B, Plant G, Graham E. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. 2003;126(2):276-84.

Keja K, Chan C, Hayden G, Henderson RH. Expanded programme on immunization. World Health Stat Q. 1988;41(2):59-63.

Thailand TNIo. Clinical Practice Guidelines: Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder 2018 [cited 2022 19 September]. Available from: http://neurothai.org/media/news_file/309-9-2561%20Clinical%20practice%20guideline%20MS%20and%20NMOSD.pdf.

Manouchehrinia A, Tanasescu R, Kareem H, Jerca OP, Jabeen F, Shafei R, et al. Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. J Neurovirol. 2017;23(6):839-44.

Owusu JT, Prapasiri P, Ditsungnoen D, Leetongin G, Yoocharoen P, Rattanayot J, et al. Seasonal influenza vaccine coverage among high-risk populations in Thailand, 2010–2012. Vaccine. 2015;33(5):742-7.

Sirikalyanpaiboon M, Ousirimaneechai K, Phannajit J, Pitisuttithum P, Jantarabenjakul W, Chaiteerakij R, et al. COVID-19 vaccine acceptance, hesitancy, and determinants among physicians in a university-based teaching hospital in Thailand. BMC Infect Dis. 2021;21(1):1174.